Enveric Biosciences Inc vs Toronto-Dominion Bank — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while Toronto-Dominion Bank trades at $124.14 (market cap $203.96B). The key difference: Toronto-Dominion Bank is far larger — about 38338.3× Enveric Biosciences Inc's market cap, and Toronto-Dominion Bank pays a 2.53% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TD | |
|---|---|---|
Market Cap | $5.32M | $203.96B |
Sector | Health | Financials |
52-Week High | $17.40 | $124.80 |
52-Week Low | $1.28 | $72.55 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 2.53% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Toronto-Dominion Bank (TD) trades at $122.88, up 1.87% with a bullish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and a 33.5% net income margin in 2025. Analyst consensus is bullish with a $153 price target, representing 24.5% upside potential. Recent news highlights dividend increases and AI-driven operational improvements.
TD presents a compelling investment case with strong profitability, consistent earnings growth, and positive analyst sentiment. Key risks include high debt levels with a 22.1 debt-to-asset ratio and potential economic sensitivity as a major bank. The stock's current valuation at 20.8 P/E appears reasonable given growth prospects and dividend yield.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →